Ophthotech Corporation to Present at the Morgan Stanley Global Healthcare Conference
September 06 2016 - 7:30AM
Business Wire
– Webcast Available Through Ophthotech Website
–
Ophthotech Corporation (NASDAQ:OPHT) announced today that David
R. Guyer, M.D., Chief Executive Officer and Chairman of the Board,
will present at the Morgan Stanley Global Healthcare Conference in
New York, NY on Tuesday, September 13, 2016 at 10:35 a.m. Eastern
Time.
Investors and the general public are invited to listen to a live
webcast of the presentation at www.ophthotech.com. Please connect
to Ophthotech’s website several minutes prior to the start of the
presentation to ensure adequate time for any software download that
may be necessary. A replay will be available for 14 days following
the presentation.
About Ophthotech Corporation
Ophthotech is a biopharmaceutical company specializing in the
development of novel therapeutics to treat back of the eye
diseases, with a focus on developing innovative therapies for
age-related macular degeneration (AMD). Ophthotech's most advanced
product candidate, Fovista® anti-PDGF therapy, is in Phase 3
clinical trials for use in combination with anti-VEGF therapy that
represents the current standard of care for the treatment of wet
AMD. Ophthotech's second product candidate, Zimura®, an inhibitor
of complement factor C5, is being developed for the treatment of
geographic atrophy, a form of dry AMD, and in combination with
anti-VEGF therapy in wet AMD patients. For more information, please
visit www.ophthotech.com.
Forward-looking Statements
Any statements in this press release about Ophthotech's future
expectations, plans and prospects constitute forward-looking
statements for purposes of the safe harbor provisions under the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by such forward-looking
statements as a result of various important factors. Any
forward-looking statements represent Ophthotech's views only as of
the date of this press release. Ophthotech anticipates that
subsequent events and developments will cause its views to change.
While Ophthotech may elect to update these forward-looking
statements at some point in the future, Ophthotech specifically
disclaims any obligation to do so.
OPHT-G
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160906005152/en/
InvestorsKathy GalanteOphthotech CorporationVice
President, Investor Relations and Corporate
Communications212-845-8231kathy.galante@ophthotech.comorMediaJennifer
DevineSmithSolve LLC on behalf of Ophthotech
Corporation973-442-1555 ext. 102jennifer.devine@smithsolve.com
OPHTHOTECH CORP. (NASDAQ:OPHT)
Historical Stock Chart
From Mar 2024 to Apr 2024
OPHTHOTECH CORP. (NASDAQ:OPHT)
Historical Stock Chart
From Apr 2023 to Apr 2024